|
1
|
Ahmed RL, Schmitz KH, Anderson KE,
Rosamond WD and Folsom AR: The metabolic syndrome and risk of
incident colorectal cancer. Cancer. 107:28–36. 2006.
|
|
2
|
Stocks T, Van Hemelrijck M, Manjer J, et
al: Blood pressure and risk of cancer incidence and mortality in
the Metabolic Syndrome and Cancer Project. Hypertension.
59:802–810. 2012.
|
|
3
|
Ishino K, Mutoh M, Totsuka Y and Nakagama
H: Metabolic syndrome: A novel high-risk state for colorectal
cancer. Cancer Lett. 2012.
|
|
4
|
Shimizu M, Kubota M, Tanaka T and Moriwaki
H: Nutraceutical approach for preventing obesity-related colorectal
and liver carcinogenesis. Int J Mol Sci. 13:579–595. 2012.
|
|
5
|
Donohoe CL, Pidgeon GP, Lysaght J and
Reynolds JV: Obesity and gastrointestinal cancer. Br J Surg.
97:628–642. 2010.
|
|
6
|
Shimizu M, Shirakami Y, Iwasa J, et al:
Supplementation with branched-chain amino acids inhibits
azoxymethane-induced colonic preneoplastic lesions in male
C57BL/KsJ-db/db mice. Clin Cancer Res. 15:3068–3075. 2009.
|
|
7
|
Shimizu M, Shirakami Y, Sakai H, et al:
(−)-Epigallocatechin gallate suppresses azoxymethane-induced
colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer
Prev Res (Phila). 1:298–304. 2008.
|
|
8
|
Kubota M, Shimizu M, Sakai H, et al:
Preventive effects of curcumin on the development of
azoxymethane-induced colonic preneoplastic lesions in male
C57BL/KsJ-db/db obese mice. Nutr Cancer. 64:72–79. 2012.
|
|
9
|
Yasuda Y, Shimizu M, Shirakami Y, et al:
Pitavastatin inhibits azoxymethane-induced colonic preneoplastic
lesions in C57BL/KsJ-db/db obese mice. Cancer Sci. 101:1701–1707.
2010.
|
|
10
|
Kochi T, Shimizu M, Ohno T, et al:
Enhanced development of azoxymethane-induced colonic preneoplastic
lesions in hypertensive rats. Int J Mol Sci. 14:14700–14711.
2013.
|
|
11
|
de Kloet AD, Krause EG and Woods SC: The
renin angiotensin system and the metabolic syndrome. Physiol Behav.
100:525–534. 2010.
|
|
12
|
Chrysant SG, Chrysant GS, Chrysant C and
Shiraz M: The treatment of cardiovascular disease continuum: focus
on prevention and RAS blockade. Curr Clin Pharmacol. 5:89–95.
2010.
|
|
13
|
Fyhrquist F and Saijonmaa O:
Renin-angiotensin system revisited. J Intern Med. 264:224–236.
2008.
|
|
14
|
Fox KM; EURopean trial On reduction of
cardiac events with Perindopril in stable coronary Artery disease
Investigators. Efficacy of perindopril in reduction of
cardiovascular events among patients with stable coronary artery
disease: randomised, double-blind, placebo-controlled, multicentre
trial (the EUROPA study). Lancet. 362:782–788. 2003.
|
|
15
|
van Vark LC, Bertrand M, Akkerhuis KM, et
al: Angiotensin-converting enzyme inhibitors reduce mortality in
hypertension: a meta-analysis of randomized clinical trials of
renin-angiotensin-aldosterone system inhibitors involving 158,998
patients. Eur Heart J. 33:2088–2097. 2012.
|
|
16
|
Deshayes F and Nahmias C: Angiotensin
receptors: a new role in cancer? Trends Endocrinol Metab.
16:293–299. 2005.
|
|
17
|
George AJ, Thomas WG and Hannan RD: The
renin-angiotensin system and cancer: old dog, new tricks. Nat Rev
Cancer. 10:745–759. 2010.
|
|
18
|
Ager EI, Neo J and Christophi C: The
renin-angiotensin system and malignancy. Carcinogenesis.
29:1675–1684. 2008.
|
|
19
|
Bernardi S, Zennaro C, Palmisano S, et al:
Characterization and significance of ACE2 and Mas receptor in human
colon adenocarcinoma. J Renin Angiotensin Aldosterone Syst.
13:202–209. 2012.
|
|
20
|
Hiraoka-Yamamoto J, Nara Y, Yasui N, et
al: Establishment of a new animal model of metabolic syndrome:
SHRSP fatty (fa/fa) rats. Clin Exp Pharmacol Physiol. 31:107–109.
2004.
|
|
21
|
Ueno T, Takagi H, Fukuda N, et al:
Cardiovascular remodeling and metabolic abnormalities in SHRSP.
Z-Lepr(fa)/IzmDmcr rats as a new model of metabolic syndrome.
Hypertens Res. 31:1021–1031. 2008.
|
|
22
|
Kubota M, Shimizu M, Sakai H, et al:
Renin-angiotensin system inhibitors suppress azoxymethane-induced
colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice.
Biochem Biophys Res Commun. 410:108–113. 2011.
|
|
23
|
Ogawa K, Hara T, Shimizu M, et al:
Suppression of azoxymethane-induced colonic preneoplastic lesions
in rats by 1-methyltryptophan, an inhibitor of indoleamine
2,3-dioxygenase. Cancer Sci. 103:951–958. 2012.
|
|
24
|
Suzuki Y, Imai K, Takai K, et al:
Hepatocellular carcinoma patients with increased oxidative stress
levels are prone to recurrence after curative treatment: A
prospective case series study using the d-ROM test. J Cancer Res
Clin Oncol. in press. 2013.
|
|
25
|
Tamarat R, Silvestre JS, Durie M and Levy
BI: Angiotensin II angiogenic effect in vivo involves vascular
endothelial growth factor- and inflammation-related pathways. Lab
Invest. 82:747–756. 2002.
|
|
26
|
Chen H, Sullivan G, Yue LQ, Katz A and
Quon MJ: QUICKI is a useful index of insulin sensitivity in
subjects with hypertension. Am J Physiol Endocrinol Metab.
284:E804–812. 2003.
|
|
27
|
Shimomoto T, Ohmori H, Luo Y, et al:
Diabetes-associated angiotensin activation enhances liver
metastasis of colon cancer. Clin Exp Metastasis. 29:915–925.
2012.
|
|
28
|
Kedika R, Patel M, Pena Sahdala HN, et al:
Long-term use of angiotensin converting enzyme inhibitors is
associated with decreased incidence of advanced adenomatous colon
polyps. J Clin Gastroenterol. 45:e12–16. 2011.
|
|
29
|
Cassis P, Conti S, Remuzzi G and Benigni
A: Angiotensin receptors as determinants of life span. Pflugers
Arch. 459:325–332. 2010.
|
|
30
|
Tudek B and Speina E: Oxidatively damaged
DNA and its repair in colon carcinogenesis. Mutat Res. 736:82–92.
2012.
|
|
31
|
Valavanidis A, Vlachogianni T and Fiotakis
C: 8-hydroxy-2′-deoxyguanosine (8-OHdG): A critical biomarker of
oxidative stress and carcinogenesis. J Environ Sci Health C Environ
Carcinog Ecotoxicol Rev. 27:120–139. 2009.
|
|
32
|
Uemura H, Ishiguro H, Ishiguro Y, Hoshino
K, Takahashi S and Kubota Y: Angiotensin II induces oxidative
stress in prostate cancer. Mol Cancer Res. 6:250–258. 2008.
|
|
33
|
Smith GR and Missailidis S: Cancer,
inflammation and the AT1 and AT2 receptors. J Inflamm (Lond).
1:32004.
|
|
34
|
Yvan-Charvet L, Massiera F, Lamande N, et
al: Deficiency of angiotensin type 2 receptor rescues obesity but
not hypertension induced by overexpression of angiotensinogen in
adipose tissue. Endocrinology. 150:1421–1428. 2009.
|
